

Table 1_SuppInfo. Description of 10 studies included in the meta-analysis

Study	Years	Patient enrollment	Study design	No. of patients	Gender (M/F)	Age (year), mean (range)	Lesion
1.Park MJ	2012	consecutive	case control	260	185/75	M: 55.1(27–76);F: 56.5(40-90)	179
2.Zhao XT	2013	consecutive	case series	33	27/6	54 (20–80)	34
3.Sano K	2011	consecutive	case series	64	47/17	M:65 ; F: 71	96
4. Kim YK	2011	consecutive	case series	40	28/12	63(45–77)	54
5. Golfieri R	2011	consecutive	case series	127	91/36	54(31–77)	173
6. Kim YK	2010	consecutive	case series	41	31/10	40–74	56
7. Park G	2010	consecutive	case series	43	28/15	44-70	59
8. Sun HY	2010	consecutive	case series	69	53/13	55.8(39–73)	44
9. Faletti R	2015	consecutive	case control	28	27/1	54.7(42–66)	28
10. Hwang J	2014	consecutive	case control	63	54/9	52	68

Study	Diameter of HCC(cm)(range)	Mean time interval between MRI and histopathology	MS (T)	Dose(mmol/kg)	Cause of liver cirrhosis
1.Park MJ	1.4(0.6–2.0)	7days(3-12)	3.0	0.025	HBV(N=242), HCV(N=18)
2.Zhao XT	1.5(0.6–2.0)	30days	3.0	0.025	HBV(N=27), HCV(N=3), Alcohol(N=3)
3.Sano K	1.27(0.4–2.0)	30days	1.5	0.025	ND
4. Kim YK	1.5(0.6–2.0)	ND	3.0	0.025	HBV(N=38), HCV(N=2)
5. Golfieri R	1.6(7–20)	ND	1.5	0.025	HBV(N=44), HCV(N=65), Alcohol(N=18)
6. Kim YK	1.5(0.5–2.0)	ND	1.5	0.025	HBV(N=38), HCV(N=4)
7. Park G	1.5(0.5–2.0)	ND	1.5	0.025	HBV(N=42), HCV(N=1)
8. Sun HY	1.37(0.5-2.0)	ND	3.0	10ml	HBV(N=56), HCV(N=6), Alcohol(N=3),unknown(N=4)
9. Faletti R	ND	3(0–6) months	1.5	0.025	HBV(N=8),HCV(N=13),Alcohol(N=4), HBV+HDV(N=2),Idiopathic(N=1)
10. Hwang J	ND	36days(3-88)	3.0	0.025	HBV(N=50), HCV(N=6),HBV+HCV(N=2), Alcohol(N=3),AIH(N=1),Wilson’s disease(N=1)

Study	Reference standard	Blind to reference standard	Reviewers (year of experience)	combined with DWI
1.Park MJ	Histopathology and imaging follow up	Blind	3 Radiologists (3,7 and 11 years)	Yes
2.Zhao XT	Histopathology or imaging follow up	Blind	2 Radiologists (8 and 5 years)	Yes
3.Sano K	Histopathology	Blind	2 Radiologists (13 and 6 years)	
4. Kim YK	Histopathology or combined imaging findings/ and imaging follow up	Blind	2 faculty-level gastrointestinal radiologists	
5. Golfieri R	Histopathology/or Lipiodol uptake	Blind	2 Radiologists (more than 6 years)	
6. Kim YK	Histopathology or combined imaging findings/ and imaging follow up	Blind	2 faculty-level gastrointestinal radiologists	
7. Park G	Histopathology or combined imaging findings/ and imaging follow up	Blind	2 faculty-level gastrointestinal radiologists	

8. Sun HY	Histopathology or combined imaging findings/ and imaging follow up	Blind	2 Radiologists (12 and 5 years)	
9. Faletti R	explant	Blind	2 Radiologists (5 and 4 years)	
10. Hwang J	explant	Blind	2 Radiologists(12 and 5 years)	Yes

Note: MS (T), magnetic strength (Tesla); ND, not documented; HBV, hepatitis B; HCV, hepatitis C; HDV, hepatitis D; AIH, autoimmune hepatitis.